- KR₩62bn
- KR₩75bn
- KR₩141bn
Annual income statement for Yuyu Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 115,655 | 138,881 | 137,210 | 133,147 | 140,885 |
| Cost of Revenue | |||||
| Gross Profit | 45,335 | 53,313 | 48,897 | 51,705 | 53,941 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 114,455 | 139,917 | 137,587 | 121,799 | 130,897 |
| Operating Profit | 1,200 | -1,036 | -377 | 11,348 | 9,987 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -383 | -3,810 | -5,442 | 9,985 | 9,483 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -920 | -4,425 | -5,541 | 10,289 | 9,117 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,214 | -5,988 | -7,181 | 8,720 | 8,154 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -2,499 | -6,273 | -6,303 | 7,778 | 9,666 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -156 | -359 | -360 | 428 | 529 |
| Dividends per Share |